10月10日，皓元医药跌5.24%，截至发稿，报81.00元/股，成交2.37亿元，换手率1.35%，总市值171.80 亿元。 资料显示，上海皓元医药股份有限公司位于上海市浦东新区张衡路1999弄3号楼，成立日期2006年9月30 日，上市日期2021年6月8日，公司主营业务涉及小分子药物发现领域的分子砌块和工具化合物的研发, 以及小分子药物原料药、中间体的工艺开发和生产技术改进,为全球医药企业和科研机构提供从药物发 现到原料药和医药中间体的规模化生产的相关产品和技术服务。主营业务收入构成为：分子砌块、工具 化合物和生化试剂68.97%，其中:产品销售63.42%，原料药和中间体、制剂30.46%，其中:技术服务 5.55%，其他(补充)0.57%。 恒生前海沪港深新兴产业精选混合（004332）成立日期2017年4月1日，最新规模5668.48万。今年以来 收益43.74%，同类排名1955/8166；近一年收益40.63%，同类排名2094/8014；成立以来收益48.87%。 恒生前海沪港深新兴产业精选混合（004332）基金经理为邢程。 截至发稿，邢程累计任职时间3年203天，现任基金资产总规模2. ...

截至9月19日，皓元医药股东户数1.28万，较上期增加17.93%；人均流通股16527股，较上期减少 12.82%。2025年1月-6月，皓元医药实现营业收入13.11亿元，同比增长24.20%；归母净利润1.52亿元， 同比增长115.55%。 分红方面，皓元医药A股上市后累计派现1.43亿元。近三年，累计派现1.03亿元。 机构持仓方面，截止2025年6月30日，皓元医药十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股626.11万股，相比上期增加32.92万股。中欧医疗健康混合A（003095）位居第五大流通股 东，持股611.85万股，相比上期减少277.76万股。 责任编辑：小浪快报 10月9日，皓元医药涨3.49%，成交额5.08亿元。两融数据显示，当日皓元医药获融资买入额7022.32万 元，融资偿还6629.59万元，融资净买入392.73万元。截至10月9日，皓元医药融资融券余额合计4.16亿 元。 融资方面，皓元医药当日融资买入7022.32万元。当前融资余额4.14亿元，占流通市值的2.29%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，皓元医药10月9日融 ...

Investment Rating - The report maintains a "Buy" rating for Haoyuan Pharmaceutical (688131) with a target price based on the last closing price of 60.23 [1][4]. Core Insights - Haoyuan Pharmaceutical's Q2 revenue exceeded expectations, with a strong profit growth. The company achieved a revenue of 1.311 billion yuan in H1 2025, representing a year-on-year increase of 24.20%, and a net profit of 152 million yuan, up 115.55% year-on-year [4][5]. - The growth in revenue and profit is attributed to the rapid expansion of the high-margin life science reagent business and effective internal management and cost control [5][6]. - The front-end business generated 904 million yuan in revenue in H1 2025, a 29.2% increase year-on-year, with a gross margin of 63.0%, up 3.5 percentage points [5][6]. Revenue and Profit Forecast - The company forecasts revenues of 2.848 billion yuan, 3.598 billion yuan, and 4.564 billion yuan for 2025, 2026, and 2027, respectively, with growth rates of 25.47%, 26.33%, and 26.84% [6][7]. - The net profit is expected to reach 308 million yuan, 399 million yuan, and 517 million yuan for the same years, with growth rates of 52.65%, 29.56%, and 29.75% [6][7]. Business Segments Performance - The front-end business's revenue accounted for a significant portion of total revenue, with 9.04 billion yuan in H1 2025, while the back-end business generated 399 million yuan, reflecting a 13.6% year-on-year increase [5][6]. - The back-end business has a robust order backlog exceeding 590 million yuan, a 40.1% increase year-on-year, indicating strong future growth potential [6].

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its business operations and financial performance. Group 1: Main Business Operations - The company reported a total revenue of 2,253.67 million yuan from its research and experimental development sector in 2024, with a year-on-year growth of 32.41% in the front-end molecular building blocks and tool compounds business, generating 1,499.07 million yuan [1][4] - The product sales revenue in this segment was 1,363.90 million yuan, reflecting a 36.01% increase, while the gross profit margin stood at 63.74% [1][4] - The back-end raw materials and intermediates development business generated 754.61 million yuan, with a modest year-on-year growth of 2.49%, but product sales in this segment saw a decline of 30.45% [1][4] Group 2: Revenue and Profitability Analysis - Domestic and overseas business revenues were 1,391.69 million yuan and 861.99 million yuan respectively, with gross profit margins of 38.82% and 46.8% [1][4] - The company provided a detailed breakdown of its four business segments, including revenue, gross profit margins, and year-on-year changes, indicating a comprehensive analysis of market size and competitive landscape [1][4][6] Group 3: Market Trends and Growth Potential - The global pharmaceutical R&D expenditure is projected to grow at a rate of 4.2% annually, reaching 254 billion USD by 2026, which is expected to positively impact the life sciences reagent market [6][7] - The Chinese research reagent market has expanded from approximately 25 billion yuan in 2018 to about 48 billion yuan in 2022, with a compound annual growth rate of around 18% [6][7] - The global CDMO market is also on a growth trajectory, with expectations to reach 124.3 billion USD by 2025, indicating a robust demand for innovative drug development services [9][10] Group 4: Competitive Positioning - The company has established itself as a competitive player in the life sciences reagent sector, particularly in the molecular building blocks and tool compounds market, which is characterized by strong customization capabilities and a growing customer base [2][4] - The company’s tool compounds business is positioned favorably compared to peers, with higher revenue growth and gross profit margins, reflecting its strong international influence [11][12] - The company’s performance in the generic drug intermediates and raw materials sector aligns with industry trends, with a notable increase in the market for high-end pharmaceutical intermediates [13][14]